A recent study utilizing a mouse model identified that the absence of the angiopoietin-like 4 (ANGPTL4) protein during development leads to a lasting reprogramming of the immune system. This reprogramming provides protection against intestinal inflammation. The findings, published in The American Journal of Pathology, may offer important implications for identifying molecular or cellular signatures that predict disease susceptibility and for developing therapeutic strategies to enhance protective immune programs in inflammatory bowel disease (IBD) and inflammation-driven colorectal cancer.
ANGPTL4: Beyond Lipid Metabolism
ANGNTPL4 is a secreted glycoprotein primarily recognized for its role in lipid metabolism. Beyond its metabolic functions, ANGPTL4 is important for tissue stability and health (homeostasis) and has been implicated in various disease processes including cancer, wound healing, pulmonary inflammation, atherosclerosis, and notably, intestinal homeostasis.
The intestine is an important organ for nutrient absorption and immune defense, continuously exposed to numerous antigens and microbes. Disruptions in intestinal homeostasis can result in pathological outcomes, such as IBD and colitis, with prolonged inflammation increasing the risk of colorectal cancer.
Unpacking the Angptl4 Knockout Survivors
Previous research on Angptl4 knockout mice (with the gene "switched off") revealed a complex picture. While some pups died within the first two weeks of life due to impaired intestinal lymphatic development and severe intestinal inflammation, survivors developed normally without apparent lymphatic defects.
This study focused on the long-term health of these surviving Angptl4 knockout mice. Researchers hypothesized that these surviving mice might undergo developmental adaptation to overcome early intestinal challenges. They investigated how these surviving mice would respond later in life when exposed to intestinal inflammation, and what the long-term consequences of Angptl4 deficiency in inflammatory settings would be.
Unexpected Protection Against Inflammation and Cancer
Unexpectedly, these mice were strongly protected against both intestinal inflammation and inflammation-driven colon tumors when compared with normal, wild-type controls. This protection was associated with a shift in macrophage (a type of immune cell) behavior toward an alternatively activated state, suggesting that altered immune responses contribute to reduced disease severity and tumor formation.
"A major insight from the study is that intestinal inflammation experienced during development can shape long-term immune programming, resulting in increased resistance to recurrent inflammatory challenges later in life."
Understanding how early-life inflammatory events "train" or reprogram intestinal immune responses may reveal new mechanisms by which the body prepares for future inflammatory insults.
Human Relevance: ANGPTL4 as a Prognostic Biomarker
To evaluate the clinical relevance in human colorectal cancer, The Cancer Genome Atlas Colorectal Adenocarcinoma data set was analyzed. This analysis showed that low ANGPTL4 expression levels correlated with lower inflammatory levels and improved survival rates in human colorectal adenocarcinoma.
These findings present a previously unrecognized impact of Angptl4 deficiency in intestinal pathogenesis and support the concept of trained immunity (epigenetic programming), in which early-life exposures can induce long-lasting reprogramming of the innate immune system.
The study highlights the significance of ANGPTL4 as a prognostic biomarker for bowel inflammation and colorectal cancer. Understanding the distinct roles of ANGPTL4 in different tissues will be crucial for developing targeted therapies that maximize benefits while minimizing adverse effects.